Date: 2015-09-17
Type of information: Licensing agreement
Compound: lentivirus packaging cell lines based on CEVEC’s proprietary CAP®GT technology
Company: CEVEC Pharmaceuticals (Germany) Genethon (France)
Therapeutic area: Rare diseases - Technology - Services
Type agreement: licensing collaboration
Action mechanism: The CAP®GT expression platform provides a fully scalable, regulatory endorsed production system for gene therapy vectors. CAP®GT cells grow to high cell densities and show a broad viral propagation spectrum including lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV). Furthermore, CAP®GT enables easier scale-up and reduced production costs when compared to adherent cell culture systems.
Disease:
Details: * On September 17, 2015, Cevec Pharmaceuticals, a producer of tailor-made recombinant glycoproteins and gene therapy vectors, announced a collaboration agreement with Généthon for the development and exploitation of lentivirus packaging cell lines based on Cevec’s proprietary CAP®GT technology. Under the terms of the agreement, Cevec will grant Généthon a license for the development of lentivirus packaging cell lines based on Cevec’s CAP®GT technology to be used with its own portfolio of gene therapy products in the field of rare diseases. Furthermore, Généthon will offer its development and production expertise to manufacture CAP®GT derived lentiviral vectors for its partners. Cevec will offer the required licenses for its CAP®GT technology to Généthon‘s partners.
Financial terms: Financial details of this agreement were not disclosed.
Latest news:
